BioPharm, Validating Analytical Methods For Bio Pharmaceuticals, Part 1

BioPharm International: Validating Analytical Methods for Biopharmaceuticals, Part 1: Development an...
Page 1 of 9
October 1, 2004
Validating Analytical Methods for Biopharmaceuticals, Part 1: Development and

Optimization
By Stephan Krause, PhD
Validation of analytical methods can be more easily accomplished by breaking the task down into a series of planned
steps.
Regulatory guidance documents are written by committees, resulting in statements that are both exact and generic. Meeting regulatory
requirements involves not only interpreting these documents correctly but also addressing their omissions. This article provides practical guidance
on issues that are not thoroughly covered by current guidance documents regarding validation of analytical methods for biopharmaceuticals.
Four of the key regulatory guidance documents on methods validation state, "Methods validation is the process of
demonstrating that analytical procedures are suitable for their intended use." 1-4 We have all read, and likely used, this phrase
many times when summarizing method-validation results. However, according to Muire-Sluis, development scientists often
point out that "validated methods may not be valid."5 The question therefore arises, what exactly makes a validated method
valid? According to CBER, "the acceptability of analytical data corresponds directly to the criteria used to validate the
method."4
We can generate evidence for the validity of analytical data in the formal method-validation program where all critical
parameters are extensively tested under a detailed protocol that includes scientifically justified and logical step-by-step
Figure 1: Process Map of experimental approaches. All planned data sets must fall within pre-established protocol acceptance criteria (limits). These
Analytical Method
Development and
criteria should be derived from and justified in relation to historical data and product specifications. Once evidence for all
Validation critical elements is provided, the validated method will become the official, licensed procedure for that particular product and
process step, and it will then support production and product release. The relationship between "valid" or "suitable and validated" is often
overlooked, but there is a high price when "validated" test systems are simply inappropriate.
Incentives to replace existing licensed test procedures may come from regulatory agencies, or they could be motivated by potential cost savings,
ease of use (automation), and the opportunity to generate more accurate and reliable results.
The International Conference on Harmonisation (ICH)'s Q2A and Q2B1,2 and the United States Pharmacopoeia's USP 27 <1225> 6 should be
used for basic guidance. However, following just these guidelines will not necessarily produce a "valid" method and may not provide sufficient
evidence that this method is suitable for product release. FDA provides guidance on some of the scientific issues that are not covered by Q2A
and Q2B or USP 27.3,4,6
Process Map. A process map showing the recommended steps for the selection, development, validation, and potential transfer of analytical
methods, illustrating all functional responsibilities was developed. Frequently, larger companies have separate functional units for method
development, validation, and testing. The process flow in Figure 1 describes an ideal sequence of steps for better analytical method validation
(AMV).
The rigorous standards suggested here are ideal, but they are not necessarily required or followed during method development. Methods can be
developed without strict adherence to GMP regulations if adequate documentation systems are used.
ANALYTICAL METHOD SELECTION Many new technologies are now available for biopharmaceutical
development.5 These analytical advances and their appropriate application are discussed in detail in the
http://license.icopyright.net/user/viewFreeUse.act?fuid=NDAyNDgyNA%3D%3D 7/2/2009
BioPharm International: Validating Analytical Methods for Biopharmaceuticals, Part 1: Development an... Page 2 of 9
literature.7-9 Since these technologies are constantly improving — resulting in shorter testing times and
increased throughput, ease of use, sensitivity, selectivity, and precision — at some point existing methods will be
replaced with better ones. Automating a procedure, resulting in long-term savings and fewer operator errors, is
one reason to undertake this process. A more-sensitive method may increase the likelihood of observing
impurities at an upstream process stage where corrective action is less expensive.
Whether it is the initial license procedure, an update, or a replacement to a licensed procedure, qualified
Table 1. Validation Characteristics per ICH
personnel should carefully select a new test methodology and its appropriate instrumentation. Changing Q2A and Q2B and Relevant Product
biological assays (for instance, impurity testing by ELISA) requires extra care. Muire-Sluis documented that Specifications
accuracy (analyte recovery) of biological assays is often highly dependent on the standard and method used. 5 Literature should be reviewed
before selecting a new method. Accuracy is a prime consideration, since any bias in results must be reflected in the release specifications.10
When replacing existing technologies with automated or more sensitive ones, alert and action levels and associated specifications must be
adjusted if needed. In-process and product specifications should reflect production-process consistency and analytical capabilities — unless
otherwise dictated by regulatory authorities.10
Current GMP guidelines state that GMP documentation and the detail of validation activities should increase as the production process
progresses.11 Testing upstream stages may actually be more critical than many final container release tests because it provides evidence of
fermentation quality and the efficiency of impurity removal — although the tests are more uncertain and variable. Final container testing attests
that formulation excipients remain at predicted levels with little variability.
Science-and risk-based testing should carefully evaluate different product quality attributes that can impact overall product quality. Testing for in-
process impurities (like host cell proteins) should emphasize overall measurement sensitivity, selectivity, and precision. In other words, the
analytical method should clearly detect batch-to-batch variations; whether the measurements are extremely accurate (100% recovery) is not as
important. This contravenes current GMP guidelines that state that the level of GMP documentation and the details of validation activities should
somehow increase with the progression of the production process.11
Some of the most advanced and innovative analytical technologies may be extremely informative for
characterization of product, impurities, or the product matrix but may not be appropriate for product release
testing. When selecting an appropriate quality control (QC) method, the pros and cons should be carefully
weighed against each other. Solid evidence that the new method will provide equivalent or better results is
necessary when submitting a license change to regulatory authorities. The method's requirements should be
similar to instrument requirements and based on the expected capability of the new method, as determined by a
careful data review and identification of critical assay characteristics.
ANALYTICAL METHOD DEVELOPMENT It is the responsibility of the analytical method development (AMD)
scientist to include the test method's details in the standard operating procedure (SOP), including optimization of
Figure 2: Graphical Representation of In-
assay elements (such as mixing volumes and statistical data reduction). If practical, all AMD data should ideally
Process and Product Specifications
be generated in a GMP environment. In other words, we should generate all development data with qualified equipment by qualified personnel,
and properly document and summarize the data in an AMD report approved by quality assurance (QA).
Oftentimes, methods are not developed from the ground up but rather only optimized for a particular product and product matrix. In any case,
always follow a thorough optimization process, which includes incorporating the best-fit data reduction function (for example, five-parameter,
logistic parallel-line statistics for an ELISA assay). 12,13
A well-planned and controlled experimental design that emphasizes QC release-testing suitability will prevent multiple, unsuccessful trial-and-
error efforts. Scientific and regulatory concerns must be balanced with potential economical restrictions. There are excellent tools published by
the American Society for Standards and Testing (ASTM) to establish efficient design of experiment (DOE) templates and to help establish
appropriate system suitability criteria.14-18
QA approval is required at many points in method development and validation (as indicated in red in Figure 1). Ideally, the process does not
continue until it has been approved. Data generated using a final, optimized method may be used to set acceptance criteria for the AMV protocol.
All instruments and equipment should be qualified and all relevant software should be validated, ensuring that all AMD data and results
(summarized later in the AMV protocol) are valid from a compliance perspective. The main tasks of analytical method development and
optimization (indicated in yellow in Figure 1) are discussed below.
ICH Q2A/B Validation. The ICH Q2A and Q2B validation requirements should be evaluated twice: once (at least partially) during or after method
optimization and once during the AMV studies. We need to know before writing the AMV protocol whether the method is suitable for the target
specifications — as well as in comparison to the current method's in-process and product specifications. Table 1 lists all validation characteristics
that typically must be evaluated for each analytical procedure. The corresponding anticipated in-process and product specifications for the new
method form a checklist. An alternate, graphical presentation of the product specifications can be found in Figure 2. This is for a typical example,
not a universal table.
Results within and outside the product specifications must be reliable. If the boundaries are fuzzy it is not possible to clearly differentiate between
acceptable and unacceptable (out-of-specification) results, and material may be improperly accepted or rejected. The analytical method and
instrumentation must be capable of bracketing the assay ranges required by ICH Q2B (illustrated with red arrows in Figure 2) to ensure that these
requirements can be met during AMD, AMV, and routine testing. This is why it is critical that instrument and method requirements (design
qualifications) are thoroughly considered during selection of the new method. Details of the ICH validation characteristics will be covered in Part II
of this article.
Assay Bias and Analyte Response Factors. All analytical procedures are associated with a degree of bias, particularly biological assays that
test for the purity, potency, and molecular interactions of biopharmaceuticals.5 Also, appropriate reference standards may not be readily available,
as the product may be one of a kind. The evaluation of the assay's accuracy and bias can be the most difficult part of the development and
validation process. Comparing the results of the new method to those of the old method is often meaningful only when accounting for assay bias.
As long as we can compensate for the bias by modifying release specifications, we should be able to properly assess the quality of the production
process and the product and remain in compliance.
Accuracy can be estimated by measuring the recovery of various spiked levels of particular analytes. Many critical assays of
product purification efficiency and product quality determine product purity and impurities simultaneously (for example, protein
composition by CZE or HP-SEC). Whenever relative percentages of various analytes are estimated using a single assay, response
factors must be established and integrated (normalized) in the calculations in order to accurately report purity and impurity levels.
Using different detectors to measure analyte signals (for example, HP-SEC with UV detection to measure protein aggregation
versus laser-light scattering or refractive-index detection) affects these relative percentages and should be thoroughly evaluated
during AMD. A simple way to directly compare response factors from various detectors during AMD is to connect all detectors in-
parallel (or inline).9
Stability. Samples, standards (secondary, in-house, or working), controls, and critical reagents should be evaluated for Nomenclature
degradation during storage and potential freeze-thaw cycles. For final container testing, the analyte and matrix of samples, in-
house standards, and controls may be similar since they all could come from the same production process. In any case, the negative effects of
time on the bench during actual testing (room temperature), repetitive freeze-thaw cycles, and long-term storage of all materials used to generate
test results should be evaluated and expiration times should be established. Reviewing and integrating historical data from the previous
development and validation of the current method or the stability program may save time. Reagent expiration times should be evaluated carefully
— any degradation could negatively impact test result quality. In general, vendor certificates of analysis can be used as evidence of reagent
stability unless reagents are diluted or otherwise changed before storage and use.
System Suitability. The test system must be properly controlled to ensure reliable release-testing results. The system suitability criteria should
be established during the AMD and optimization phase. This is usually accomplished by running a set of control points. For each test, system
suitability will be satisfied (valid test results generated) if all control points are within established limits. A test system must be able to reproduce
measurable results of a homogeneous sample (control) to allow examination of differences between batches. Small differences in batches are
normal and acceptable, but the sources of variation should be identified. Ultimately, we will have more certainty when we can separate
differences in production batches from assay variability.16-17
Sample Suitability. Technically, sample suitability is part of system suitability so these parameters can be evaluated together. Sample suitability
should be established during AMD and should ideally ensure that samples, controls, and standards are prepared identically and run
simultaneously. In addition, sample suitability should include a statistical analysis of the number of replicates needed to generate significant
release results. Single measurements may be acceptable if the production-process sampling can deliver truly batch-representative samples and
the precision of assay repeatability is high compared to the product specifications — and therefore high compared to the batch-to-batch variation
upon which these specifications are based. Often, however, assay precision is relatively low, and multiple measurements will substantially
increase the level of certainty in the corresponding test results. Several detailed standard practices are published by ASTM.14-18
Also, we should evaluate batch sampling to ensure capturing and accounting for apparent variability. For example, product potency in final
containers may vary among samples taken from the beginning, middle, and end of fill due to protein adsorption or protein aggregation during fill.
In this case, samples should be taken from each of the three fill stages to ensure a more accurate representation of the batch's average
potency.16,17
Statistical Data Reduction. Technically, statistical data analysis also is part of overall system suitability. Use multiple statistical values (for
instance, regression line correlation coefficients or p-values for the testing of standard-to-sample line parallelism) to verify that test system
performance is acceptable.
Sometimes, data transformation (for example, logarithmic conversion) may lead to improved linearity. However, most biological assay response
curves are not linear even after mathematical transformation.12,13 These are particularly difficult to deal with and should only be handled by
experienced statisticians. Non-linear models, such as four or five-parameter logistic functions with weighted factors and tests for parallelism, may
be the best approach.12,13 Just as different test methodologies have different biases, changing statistical models may significantly change the
final results. Some models may simply be inappropriate or may not provide acceptable results over the entire assay range.12,13
Robustness. Robustness, defined as the lack of a significant effect when small changes are deliberately introduced into the test system, should
ideally be addressed during the method optimization phase and not as part of AMV. We should know the degree of robustness of a method
before starting the formal AMV phase. Critical test system parameters (for example, the acceptable range of diluting the test sample) must be
identified and controlled with appropriate operational limits. These limits should be described in the AMD report and documented in the method
SOP. The SOP will then contain operational limits which are within the context of the overall system suitability criteria and which are adhered to
during the validation phase. In addition, robustness should be tested in the AMD phase during or after method optimization because significant
differences in the AMV results (from challenging the critical operational limits) may be difficult to explain in the AMV report.
We must remember that AMV is the formal evidence that this method is suitable to be used under strictly controlled QC-testing conditions. The
AMV protocol should be set up to deliver this evidence through appropriate acceptance criteria by varying sample batches and concentrations,
operators, instruments, days, and other factors that are expected to vary during routine testing — within established sample and system suitability
conditions and operational limits.19-21
ACKNOWLEDGEMENT I would like to thank Patricia Bonaz and BioPharm International's editorial board for their helpful review of this article.
REFERENCES 1. ICH. Validation of Analytical Procedures. Q2A. Federal Register 1995; 60.
2. ICH. Validation of Analytical Procedures: methodology. Q2B. Federal Register 1996; 62.
3. CDER. Guidance for Industry. Bioanalytical Method Validation. Bethesda MD: FDA; 2001.
4. CBER. Draft Guidance for Industry. Analytical Procedures and Methods Validation. Bethesda MD: FDA; 2000.
5. Muire-Sluis A. Update on regulatory and industry perspective on the design and optimization of immunogenicity assays. Presented at Biological
Assay Development and Validation; 2004 Apr 26-28; San Diego, CA.
6. United States Pharmacopoeia. USP 27 <1225>. Validation of Compendial Methods. Presented at USP Convention; 2003 Nov 21.
7. Schenerman MA, et al. CMC strategy forum report: analysis and structure characterization of monoclonal antibodies. BioProcess International
2004; (2):42-53.
8. Lucy PK and Beri RG. Key considerations in process transfer. BioProcess International 2003; (8):36-43.
9. Nguyen LT, et al. Characterization methods for the physical stability of biopharmaceuticals. PDA J. Pharm. Sci. Technol. 2003; 57(6):429-45.
10. ICH. Specifications: test procedures and acceptance criteria for biotechnological/biological products. Q6B. ICH Harmonized Tripartite
Guideline. Geneva, Switzerland: ICH; 1999.
11. ICH. Good manufacturing practice guide for active pharmaceutical ingredients. Q7A. Draft Consensus Guideline. Geneva, Switzerland: ICH;
2000.
12. Capen R. Revising USP <111> Design and analysis of bioassays: current status and future plans. Presented at Biological Assay
Development and Validation; 2004 Apr 26-28; San Diego, CA.
13. Callahan J. New USP guidelines for parallelism. Presented at Biological Assay Development and Validation; 2004 Apr 26-28; San Diego, CA.
14. ASTM. Standard guide for statistical procedures to use in developing and applying test methods. ASTM E 1488-02. West Conshohocken
(PA): ASTM; 2002.
15. ASTM. Standard guide for conducting ruggedness tests. ASTM E 1169-02. West Conshohocken (PA): ASTM; 2002.
16. ASTM. Standard guide for reducing test variability. ASTM D 4853-97. West Conshohocken (PA): ASTM; 1997.
17. ASTM. Standard guide for estimating the magnitude of variability from expected sources in sampling plans. ASTM D 4854-95. West
Conshohocken (PA): ASTM; 1995.
18. ASTM. Standard practice for comparing test methods. ASTM D 4855-97. West Conshohocken (PA): ASTM; 1997.
19. Krause SO. Good analytical method validation practice, part I: setting-up for compliance and efficiency. Journal of Validation Technology
2002; (9):23-32.
20. Krause SO. Good analytical method validation practice, part II: deriving acceptance criteria for the AMV protocol. Journal of Validation
Technology 2003; (9):162-78.
21. Krause SO. Good analytical method validation practice, part III: data analysis and the AMV report. Journal of Validation Technology 2003;
(10):21-36.
Figure 1: Process Map of Analytical Method Development and Validation
Table 1. Validation Characteristics per ICH Q2A and Q2B and Relevant Product Specifications
Nomenclature
Figure 2: Graphical Representation of In-Process and Product Specifications
© 2004 Advanstar Communications Inc.. Permission granted for up to 5 copies. All rights reserved.
You may forward this article or get additional permissions by typing http://license.icopyright.net/3.7443?icx_id=132787 into any web browser. Advanstar
Communications Inc. and BioPharm International logos are registered trademarks of Advanstar Communications Inc. The iCopyright logo is a registered trademark of iCopyright, Inc.

BioPharm, Validating Analytical Methods For Bio Pharmaceuticals, Part 1

Transféré par

Informations du document

Description originale:

Titre original

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

BioPharm, Validating Analytical Methods For Bio Pharmaceuticals, Part 1

Transféré par

Droits d'auteur :

Formats disponibles

BioPharm International: Validating Analytical Methods for Biopharmaceuticals, Part 1: Development an...

Validating Analytical Methods for Biopharmaceuticals, Part 1: Development and

Technology 2003; (9):162-78.

Figure 1: Process Map of Analytical Method Development and Validation

Vous aimerez peut-être aussi